Alpha‐Galactosidase A Activity Levels in Turkish Male Hemodialysis Patients
- 13 August 2012
- journal article
- case report
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 16 (6) , 560-565
Abstract
Fabry disease is an X‐linked lysosomal storage disorder due to deficient activity of alpha‐galactosidase A (α‐Gal A) leading to renal insufficiency in males. The aim of present study was to investigate the level of α‐Gal A activity and to determine the prevalence of Fabry disease in a Turkish male hemodialysis population. The activity of plasma α‐Gal A was measured in a group of 808 male hemodialysis patients using fluorimetric methods. Patients with low α‐Gal A activity were evaluated clinically and genetic testing was carried out. A correlation with creatinine, uric acid, urea, white blood cell (WBC), and high sensitivity (hs)CRP and α‐Gal A activity was also investigated. Plasma α‐Gal A activity among this male population undergoing hemodialysis was 7.88 ± 5.18 µM/hour/L (0.40–55.72), significantly lower when compared to controls. No influence of creatinine, uric acid, WBC, or hsCRP on measured α‐Gal A activity was reported. Two new Fabry disease patients were identified. Both were previously diagnosed with diabetes mellitus type 2. These findings provide, for the first time, data regarding the prevalence of α‐Gal A deficiency (0.24%) in Turkish males receiving hemodialysis.Keywords
This publication has 29 references indexed in Scilit:
- Screening for Fabry Disease in Patients with Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2008
- A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient populationNephrology Dialysis Transplantation, 2006
- High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*The American Journal of Human Genetics, 2006
- Significance of screening for Fabry disease among male dialysis patientsClinical and Experimental Nephrology, 2005
- Fabry Disease in Patients with End-Stage Renal Failure: The Potential Benefits of ScreeningNephron Clinical Practice, 2005
- Results of a Nationwide Screening for Anderson-Fabry Disease among Dialysis PatientsJournal of the American Society of Nephrology, 2004
- Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype1Kidney International, 2003
- -Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry diseaseNephrology Dialysis Transplantation, 2003
- Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement TherapyAnnals of Internal Medicine, 2003
- Fabry disease in patients receiving maintenance dialysisClinical and Experimental Nephrology, 2000